WO2022198378A1 - Composition inhibitrice de bêta-lactamases présentant une qualité stable, utilisation et méthode associées - Google Patents
Composition inhibitrice de bêta-lactamases présentant une qualité stable, utilisation et méthode associées Download PDFInfo
- Publication number
- WO2022198378A1 WO2022198378A1 PCT/CN2021/082063 CN2021082063W WO2022198378A1 WO 2022198378 A1 WO2022198378 A1 WO 2022198378A1 CN 2021082063 W CN2021082063 W CN 2021082063W WO 2022198378 A1 WO2022198378 A1 WO 2022198378A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- infection
- antibiotics
- ceftazidime
- lactamase inhibitor
- Prior art date
Links
- 239000003781 beta lactamase inhibitor Substances 0.000 title claims abstract description 58
- 229940126813 beta-lactamase inhibitor Drugs 0.000 title claims abstract description 58
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title abstract description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 39
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 35
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 35
- 241000894006 Bacteria Species 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 8
- 229960000484 ceftazidime Drugs 0.000 claims description 44
- 229960005256 sulbactam Drugs 0.000 claims description 38
- 229960003865 tazobactam Drugs 0.000 claims description 38
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 claims description 35
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 claims description 34
- -1 baminocillin Chemical compound 0.000 claims description 31
- 208000015181 infectious disease Diseases 0.000 claims description 27
- 229960004261 cefotaxime Drugs 0.000 claims description 23
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims description 20
- 239000002132 β-lactam antibiotic Substances 0.000 claims description 20
- 229940124586 β-lactam antibiotics Drugs 0.000 claims description 20
- 102000006635 beta-lactamase Human genes 0.000 claims description 19
- 108090000204 Dipeptidase 1 Proteins 0.000 claims description 16
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims description 14
- 229960004682 cefoperazone Drugs 0.000 claims description 14
- 229960004755 ceftriaxone Drugs 0.000 claims description 13
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims description 13
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 11
- 208000035143 Bacterial infection Diseases 0.000 claims description 10
- 229930186147 Cephalosporin Natural products 0.000 claims description 10
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 10
- 229940124587 cephalosporin Drugs 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 9
- 150000001780 cephalosporins Chemical class 0.000 claims description 8
- 208000036209 Intraabdominal Infections Diseases 0.000 claims description 7
- 208000031729 Bacteremia Diseases 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 206010062255 Soft tissue infection Diseases 0.000 claims description 6
- 235000019371 penicillin G benzathine Nutrition 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims description 5
- 201000009906 Meningitis Diseases 0.000 claims description 5
- 208000031650 Surgical Wound Infection Diseases 0.000 claims description 5
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical group OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims description 5
- 229960003324 clavulanic acid Drugs 0.000 claims description 5
- 206010040872 skin infection Diseases 0.000 claims description 5
- 206010060968 Arthritis infective Diseases 0.000 claims description 4
- KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime axetil Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-YJBYXUATSA-N 0.000 claims description 4
- 241000588923 Citrobacter Species 0.000 claims description 4
- 241000606768 Haemophilus influenzae Species 0.000 claims description 4
- 241000588748 Klebsiella Species 0.000 claims description 4
- 206010031252 Osteomyelitis Diseases 0.000 claims description 4
- 229930182555 Penicillin Natural products 0.000 claims description 4
- 229930195708 Penicillin V Natural products 0.000 claims description 4
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- AFZFFLVORLEPPO-UVYJNCLZSA-N cefditoren pivoxil Chemical compound S([C@@H]1[C@@H](C(N1C=1C(=O)OCOC(=O)C(C)(C)C)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C/C=1SC=NC=1C AFZFFLVORLEPPO-UVYJNCLZSA-N 0.000 claims description 4
- 229960002100 cefepime Drugs 0.000 claims description 4
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 claims description 4
- 229960005090 cefpodoxime Drugs 0.000 claims description 4
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 claims description 4
- ZCCUWMICIWSJIX-NQJJCJBVSA-N ceftaroline fosamil Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OCC)C=2N=C(NP(O)(O)=O)SN=2)CC=1SC(SC=1)=NC=1C1=CC=[N+](C)C=C1 ZCCUWMICIWSJIX-NQJJCJBVSA-N 0.000 claims description 4
- 229960002620 cefuroxime axetil Drugs 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229940049954 penicillin Drugs 0.000 claims description 4
- 229940056367 penicillin v Drugs 0.000 claims description 4
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 claims description 4
- 239000000375 suspending agent Substances 0.000 claims description 4
- 241000589291 Acinetobacter Species 0.000 claims description 3
- 241000606125 Bacteroides Species 0.000 claims description 3
- 241000588914 Enterobacter Species 0.000 claims description 3
- 241000194033 Enterococcus Species 0.000 claims description 3
- 241000588655 Moraxella catarrhalis Species 0.000 claims description 3
- 241000588653 Neisseria Species 0.000 claims description 3
- 241000588767 Proteus vulgaris Species 0.000 claims description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 3
- 241000607142 Salmonella Species 0.000 claims description 3
- 241000191967 Staphylococcus aureus Species 0.000 claims description 3
- 241000194017 Streptococcus Species 0.000 claims description 3
- 229950003588 axetil Drugs 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- 229960003012 cefamandole Drugs 0.000 claims description 3
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 claims description 3
- 229940036735 ceftaroline Drugs 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 229960002260 meropenem Drugs 0.000 claims description 3
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims description 3
- 229940056360 penicillin g Drugs 0.000 claims description 3
- 229950009297 pivoxil Drugs 0.000 claims description 3
- 229940007042 proteus vulgaris Drugs 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 claims description 2
- HGGAKXAHAYOLDJ-FHZUQPTBSA-N 6alpha-[(R)-1-hydroxyethyl]-2-[(R)-tetrahydrofuran-2-yl]pen-2-em-3-carboxylic acid Chemical compound S([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1[C@H]1CCCO1 HGGAKXAHAYOLDJ-FHZUQPTBSA-N 0.000 claims description 2
- QYQDKDWGWDOFFU-IUODEOHRSA-N Cefotiam Chemical compound CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 QYQDKDWGWDOFFU-IUODEOHRSA-N 0.000 claims description 2
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims description 2
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 claims description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 2
- TYMABNNERDVXID-DLYFRVTGSA-N Panipenem Chemical compound C([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1S[C@H]1CCN(C(C)=N)C1 TYMABNNERDVXID-DLYFRVTGSA-N 0.000 claims description 2
- 241000588770 Proteus mirabilis Species 0.000 claims description 2
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims description 2
- 239000003070 absorption delaying agent Substances 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 229960003022 amoxicillin Drugs 0.000 claims description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 2
- 229960000723 ampicillin Drugs 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 229960003623 azlocillin Drugs 0.000 claims description 2
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 claims description 2
- BVGLIYRKPOITBQ-ANPZCEIESA-N benzylpenicillin benzathine Chemical compound C=1C=CC=CC=1C[NH2+]CC[NH2+]CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 BVGLIYRKPOITBQ-ANPZCEIESA-N 0.000 claims description 2
- MRMBZHPJVKCOMA-YJFSRANCSA-N biapenem Chemical compound C1N2C=NC=[N+]2CC1SC([C@@H]1C)=C(C([O-])=O)N2[C@H]1[C@@H]([C@H](O)C)C2=O MRMBZHPJVKCOMA-YJFSRANCSA-N 0.000 claims description 2
- 229960003169 biapenem Drugs 0.000 claims description 2
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims description 2
- 229960003669 carbenicillin Drugs 0.000 claims description 2
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 claims description 2
- 229960005361 cefaclor Drugs 0.000 claims description 2
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 claims description 2
- 229960004841 cefadroxil Drugs 0.000 claims description 2
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 claims description 2
- 229960001139 cefazolin Drugs 0.000 claims description 2
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims description 2
- 229960003719 cefdinir Drugs 0.000 claims description 2
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 claims description 2
- 229960004069 cefditoren Drugs 0.000 claims description 2
- 229960002142 cefditoren pivoxil Drugs 0.000 claims description 2
- 229960002129 cefixime Drugs 0.000 claims description 2
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 claims description 2
- 229960003791 cefmenoxime Drugs 0.000 claims description 2
- HJJDBAOLQAWBMH-YCRCPZNHSA-N cefmenoxime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C HJJDBAOLQAWBMH-YCRCPZNHSA-N 0.000 claims description 2
- 229960003585 cefmetazole Drugs 0.000 claims description 2
- SNBUBQHDYVFSQF-HIFRSBDPSA-N cefmetazole Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 claims description 2
- 229960002025 cefminox Drugs 0.000 claims description 2
- JSDXOWVAHXDYCU-VXSYNFHWSA-N cefminox Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSC[C@@H](N)C(O)=O)OC)CC=1CSC1=NN=NN1C JSDXOWVAHXDYCU-VXSYNFHWSA-N 0.000 claims description 2
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 claims description 2
- 229960005495 cefotetan Drugs 0.000 claims description 2
- 229960001242 cefotiam Drugs 0.000 claims description 2
- 229960002682 cefoxitin Drugs 0.000 claims description 2
- 229960005446 cefpiramide Drugs 0.000 claims description 2
- PWAUCHMQEXVFJR-PMAPCBKXSA-N cefpiramide Chemical compound C1=NC(C)=CC(O)=C1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 PWAUCHMQEXVFJR-PMAPCBKXSA-N 0.000 claims description 2
- 229960000466 cefpirome Drugs 0.000 claims description 2
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 claims description 2
- 229960002580 cefprozil Drugs 0.000 claims description 2
- 229960002588 cefradine Drugs 0.000 claims description 2
- 229960003202 cefsulodin Drugs 0.000 claims description 2
- SYLKGLMBLAAGSC-QLVMHMETSA-N cefsulodin Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@@H](C=3C=CC=CC=3)S(O)(=O)=O)[C@H]2SC1 SYLKGLMBLAAGSC-QLVMHMETSA-N 0.000 claims description 2
- 229960001991 ceftizoxime Drugs 0.000 claims description 2
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 claims description 2
- 229960001668 cefuroxime Drugs 0.000 claims description 2
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims description 2
- 229940106164 cephalexin Drugs 0.000 claims description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims description 2
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 claims description 2
- 229960003326 cloxacillin Drugs 0.000 claims description 2
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 229960001585 dicloxacillin Drugs 0.000 claims description 2
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 claims description 2
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 claims description 2
- 229960000895 doripenem Drugs 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 229960002457 epicillin Drugs 0.000 claims description 2
- RPBAFSBGYDKNRG-NJBDSQKTSA-N epicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CCC=CC1 RPBAFSBGYDKNRG-NJBDSQKTSA-N 0.000 claims description 2
- 229960002770 ertapenem Drugs 0.000 claims description 2
- 229960000379 faropenem Drugs 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 229960004273 floxacillin Drugs 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 229960003884 hetacillin Drugs 0.000 claims description 2
- DXVUYOAEDJXBPY-NFFDBFGFSA-N hetacillin Chemical compound C1([C@@H]2C(=O)N(C(N2)(C)C)[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 DXVUYOAEDJXBPY-NFFDBFGFSA-N 0.000 claims description 2
- 229960002182 imipenem Drugs 0.000 claims description 2
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 229960003085 meticillin Drugs 0.000 claims description 2
- 229960000198 mezlocillin Drugs 0.000 claims description 2
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- WIDKTXGNSOORHA-CJHXQPGBSA-N n,n'-dibenzylethane-1,2-diamine;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;tetrahydrate Chemical compound O.O.O.O.C=1C=CC=CC=1CNCCNCC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 WIDKTXGNSOORHA-CJHXQPGBSA-N 0.000 claims description 2
- 229960000515 nafcillin Drugs 0.000 claims description 2
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 229960001019 oxacillin Drugs 0.000 claims description 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 claims description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- 229950011346 panipenem Drugs 0.000 claims description 2
- HHXMXAQDOUCLDN-RXMQYKEDSA-N penem Chemical compound S1C=CN2C(=O)C[C@H]21 HHXMXAQDOUCLDN-RXMQYKEDSA-N 0.000 claims description 2
- BBTOYUUSUQNIIY-ANPZCEIESA-N phenoxymethylpenicillin benzathine Chemical compound C=1C=CC=CC=1C[NH2+]CC[NH2+]CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 BBTOYUUSUQNIIY-ANPZCEIESA-N 0.000 claims description 2
- 229960002292 piperacillin Drugs 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000003380 propellant Substances 0.000 claims description 2
- HOCWPKXKMNXINF-XQERAMJGSA-N propicillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(CC)OC1=CC=CC=C1 HOCWPKXKMNXINF-XQERAMJGSA-N 0.000 claims description 2
- 229960003672 propicillin Drugs 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000006068 taste-masking agent Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 239000006211 transdermal dosage form Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 claims 7
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 claims 5
- KECCBFYFEOTIBV-UHFFFAOYSA-N (+)-Aspicilin Natural products CC1CCCCCCCCCCC(O)C(O)C(O)C=CC(=O)O1 KECCBFYFEOTIBV-UHFFFAOYSA-N 0.000 claims 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 claims 1
- 241001478240 Coccus Species 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 229960004099 azithromycin Drugs 0.000 claims 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims 1
- 229960003644 aztreonam Drugs 0.000 claims 1
- 229960000717 carindacillin Drugs 0.000 claims 1
- JIRBAUWICKGBFE-MNRDOXJOSA-N carindacillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(=O)OC=1C=C2CCCC2=CC=1)C1=CC=CC=C1 JIRBAUWICKGBFE-MNRDOXJOSA-N 0.000 claims 1
- JYXACOFERDBGGQ-RHSMWYFYSA-N cefathiamidine Chemical compound S1CC(COC(C)=O)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CSC(NC(C)C)=NC(C)C)[C@H]21 JYXACOFERDBGGQ-RHSMWYFYSA-N 0.000 claims 1
- 229950005040 cefathiamidine Drugs 0.000 claims 1
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 claims 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 38
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 37
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 19
- 239000012535 impurity Substances 0.000 description 17
- 239000004480 active ingredient Substances 0.000 description 15
- 239000002253 acid Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 238000007142 ring opening reaction Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 10
- 230000003115 biocidal effect Effects 0.000 description 8
- 239000002872 contrast media Substances 0.000 description 8
- 230000000670 limiting effect Effects 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000012453 solvate Substances 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 150000004677 hydrates Chemical class 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000004584 weight gain Effects 0.000 description 7
- 235000019786 weight gain Nutrition 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 5
- 238000013112 stability test Methods 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229940039231 contrast media Drugs 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 108020004256 Beta-lactamase Proteins 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- MQLRYUCJDNBWMV-GHXIOONMSA-N cefetamet Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 MQLRYUCJDNBWMV-GHXIOONMSA-N 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229960002379 avibactam Drugs 0.000 description 2
- NDCUAPJVLWFHHB-UHNVWZDZSA-N avibactam Chemical compound C1N2[C@H](C(N)=O)CC[C@@]1([H])N(OS(O)(=O)=O)C2=O NDCUAPJVLWFHHB-UHNVWZDZSA-N 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 125000003460 beta-lactamyl group Chemical group 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229960004041 cefetamet Drugs 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 210000002229 urogenital system Anatomy 0.000 description 2
- KMEGBUCIGMEPME-LQYKFRDPSA-N (2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(1r,4s)-3,3-dimethyl-2,2,6-trioxo-2$l^{6}-thiabicyclo[3.2.0]heptane-4-carboxylic acid Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)C2C(=O)C[C@H]21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 KMEGBUCIGMEPME-LQYKFRDPSA-N 0.000 description 1
- NDIURPSCHWTXDC-UHFFFAOYSA-N 2-(4,5-dimethoxy-2-nitrophenyl)acetohydrazide Chemical compound COC1=CC(CC(=O)NN)=C([N+]([O-])=O)C=C1OC NDIURPSCHWTXDC-UHFFFAOYSA-N 0.000 description 1
- KGWHMDCQVDMTNZ-UHFFFAOYSA-N 2-(butylcarbamoylamino)acetic acid Chemical compound CCCCNC(=O)NCC(O)=O KGWHMDCQVDMTNZ-UHFFFAOYSA-N 0.000 description 1
- 206010060921 Abdominal abscess Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000000197 Acute Cholecystitis Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- NCFTXMQPRQZFMZ-WERGMSTESA-M Cefoperazone sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C([O-])=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 NCFTXMQPRQZFMZ-WERGMSTESA-M 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- 206010008614 Cholecystitis acute Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000219470 Mirabilis Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NKZMPZCWBSWAOX-IBTYICNHSA-M Sulbactam sodium Chemical compound [Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)N2C(=O)C[C@H]21 NKZMPZCWBSWAOX-IBTYICNHSA-M 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- DBPPRLRVDVJOCL-FQRUVTKNSA-N cefiderocol Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1(CCNC(=O)C=2C(=C(O)C(O)=CC=2)Cl)CCCC1 DBPPRLRVDVJOCL-FQRUVTKNSA-N 0.000 description 1
- 229950000788 cefiderocol Drugs 0.000 description 1
- 229960001958 cefodizime Drugs 0.000 description 1
- XDZKBRJLTGRPSS-BGZQYGJUSA-N cefodizime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(C)=C(CC(O)=O)S1 XDZKBRJLTGRPSS-BGZQYGJUSA-N 0.000 description 1
- 229960002417 cefoperazone sodium Drugs 0.000 description 1
- 229940100303 cefotaxime injection Drugs 0.000 description 1
- 229960002727 cefotaxime sodium Drugs 0.000 description 1
- 229960004828 ceftaroline fosamil Drugs 0.000 description 1
- 229960003547 ceftazidime pentahydrate Drugs 0.000 description 1
- JEEWDSDYUSEQML-ROMZVAKDSA-M ceftazidime sodium Chemical compound [Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C([O-])=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 JEEWDSDYUSEQML-ROMZVAKDSA-M 0.000 description 1
- 229960002940 ceftazidime sodium Drugs 0.000 description 1
- 229960004241 ceftobiprole medocaril Drugs 0.000 description 1
- HFTSMHTWUFCYMJ-YIOMYIDASA-N ceftobiprole medocaril Chemical compound CC1=C(COC(=O)N2CC[C@H](C2)N2CC\C(=C/C3=C(N4[C@H](SC3)[C@H](NC(=O)C(=N/O)\C3=NSC(N)=N3)C4=O)C(O)=O)C2=O)OC(=O)O1 HFTSMHTWUFCYMJ-YIOMYIDASA-N 0.000 description 1
- JHFNIHVVXRKLEF-DCZLAGFPSA-N ceftolozane Chemical compound CN1C(N)=C(NC(=O)NCCN)C=[N+]1CC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)C(=N/OC(C)(C)C([O-])=O)\C=3N=C(N)SN=3)[C@H]2SC1 JHFNIHVVXRKLEF-DCZLAGFPSA-N 0.000 description 1
- 229960002405 ceftolozane Drugs 0.000 description 1
- 229960000479 ceftriaxone sodium Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- UCKZMPLVLCKKMO-LHLIQPBNSA-N cephamycin Chemical compound S1CC(C)=C(C(O)=O)N2C(=O)[C@@H](C)[C@]21OC UCKZMPLVLCKKMO-LHLIQPBNSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 1
- 235000019838 diammonium phosphate Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- LHVVWWADJUJFEH-HKNOZQPISA-N hexadecanoic acid (9Z,12Z)-octadeca-9,12-dienoic acid octadecanoic acid (9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid (Z)-octadec-9-enoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O.CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O LHVVWWADJUJFEH-HKNOZQPISA-N 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000003951 lactams Chemical group 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000005142 microbroth dilution method Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- AKHZTFZKWFZWRY-QVUDESDKSA-M sodium;(2s,3s,5r)-3-methyl-7-oxo-3-(triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [Na+].C([C@@]1(C)[C@@H](N2C(=O)C[C@H]2S1)C([O-])=O)N1C=CN=N1 AKHZTFZKWFZWRY-QVUDESDKSA-M 0.000 description 1
- TUPFOYXHAYOHIB-WZGOVNIISA-M sodium;(2s,5r,6r)-6-[[(2s)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]h Chemical compound [Na+].C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1.O=C1C(=O)N(CC)CCN1C(=O)N[C@@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 TUPFOYXHAYOHIB-WZGOVNIISA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 229960000614 sulbactam sodium Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960000373 tazobactam sodium Drugs 0.000 description 1
- 229940041007 third-generation cephalosporins Drugs 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 150000003952 β-lactams Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- Embodiments of the present invention relate to the technical field of medicine, and in particular, to a ⁇ -lactamase inhibitor composition with stable quality and use and method thereof.
- the antibacterial activity of ⁇ -lactamase inhibitors is basically weak, and even if they have antibacterial activity, their antibacterial spectrum is very narrow. People mainly combine ⁇ -lactamase inhibitors with antibiotics in combination or compound preparations. For example, compound preparations such as ampicillin sulbactam, piperacillin tazobactam, cefoperazone sulbactam, ceftazidime avibactam, meropenem and borbactam. In these compound preparations, a larger proportion of antibiotics is usually used to provide antibacterial activity, and a smaller proportion of ⁇ -lactamase inhibitor is used to provide ⁇ -lactamase inhibitory activity.
- ⁇ -lactamase inhibitor inhibition of ⁇ -lactamase is called "suicide inactivation", that is, after the ⁇ -lactamase inhibitor binds to ⁇ -lactamase, while the enzyme is inactivated, ⁇ -lactamase inhibits The chemical structure of the agent itself is also destroyed.
- ⁇ -lactamase inhibitors protect antibiotics from attack by ⁇ -lactamases is that their affinity for the enzyme is usually higher than that of antibiotics, but this often results in a less stable chemical structure.
- clavulanic acid is particularly sensitive to damp heat; sulbactam and tazobactam have improved stability through structural modification on the basis of clavulanic acid, but still have strong hygroscopicity.
- the increase in the moisture content of the material will lead to accelerated degradation reactions, which may lead to unqualified product quality.
- these ⁇ -lactamase inhibitors and antibiotics are made into compound preparations, it also brings risks to the stability of the compound preparations. Therefore, it is necessary to study methods for improving the stability of ⁇ -lactamase inhibitors.
- the embodiments of the present invention aim to, to a certain extent, at least solve one of the technical problems existing in the prior art.
- the first object of the present invention is to provide a pharmaceutical composition.
- the second object of the present invention is to provide the use of the above-mentioned pharmaceutical composition.
- a third object of the present invention is to provide a method of preventing or treating bacterial infection.
- the embodiment of the first aspect of the present invention provides a pharmaceutical composition comprising ceftazidime and a beta-lactamase inhibitor, wherein the weight ratio of the ceftazidime and the beta-lactamase inhibitor is less than or equal to 1:15.
- the weight ratio of ceftazidime and ⁇ -lactamase inhibitor is 1:15 ⁇ 1:2000; for example, the weight ratio is 1:15, 1:20, 1:50, 1:80, 1:100, 1 :500, 1:1000, 1:1500 or 1:2000.
- the weight ratio of the ceftazidime to the ⁇ -lactamase inhibitor is 1:15-1:1000; for example, the weight ratio is 1:15, 1:20, 1:50, 1:80, 1:100, 1:200, 1:300, 1:400, 1:500, 1:600, 1:700, 1:800, 1:900, 1:1000.
- the beta-lactamase inhibitor is selected from clavulanic acid, sulbactam or tazobactam, or any combination thereof.
- the beta-lactamase inhibitor is sulbactam and/or tazobactam.
- the ceftazidime and the beta-lactamase inhibitor are present together (eg, as a mixture).
- the pharmaceutical composition further comprises a beta-lactam antibiotic, which is not ceftazidime.
- the ⁇ -lactam antibiotics include penicillin antibiotics, penem antibiotics, carbapenem antibiotics, cephalosporin antibiotics, cephamycin antibiotics, oxycephem antibiotics and at least one of the monocyclic beta-lactam antibiotics.
- the ⁇ -lactam antibiotics are selected from the group consisting of amoxicillin, ampicillin, apoxicillin, aducillin, azlocillin, bamcillin, carbenicillin, indacillin, chloromethan Acillin, cloxacillin, dicloxacillin, epicillin, flucloxacillin, hetacillin, maytancillin, methicillin, mezlocillin, nafcillin, oxacillin, penacillin, fenecillin, Mecillin, penicillin, penicillin G, penicillin V, phenoxymethyl penicillin, piperacillin, pimacillin, propicillin, sulfenicillin, phthalicillin, temoxicillin, ticarcillin, pimecillin, benzyl Benzathine penicillin, benzathine penicillin G, benzathine penicillin V, benzathine penicillin, ce
- the ⁇ -lactam antibiotic is selected from at least one of ceftazidime, cefoperazone, cefotaxime and ceftriaxone.
- the weight ratio of the ⁇ -lactamase inhibitor to the ⁇ -lactam antibiotic is 1:1 to 1:10, for example, 1:1, 1:2, 1 :3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10.
- the ⁇ -lactam antibiotic in the pharmaceutical composition, may be present as a separate component, or may be present together with other components (eg, as a mixture). When present as separate components, they can be administered concurrently with the other components or separately. "At the same time” means at about the same time, and “separately” means at different times.
- the pharmaceutical composition further includes pharmaceutically acceptable excipients.
- the pharmaceutically acceptable excipients can be selected from any pharmaceutically acceptable excipients known in the art according to actual needs.
- the pharmaceutically acceptable excipients are selected from fillers, binders, bases, disintegrants, lubricants, solvents, solubilizers, flavoring agents, colorants, taste-masking agents, pH adjusting agents , isotonic agents, suspending agents, thickening agents, preservatives, stabilizers, antioxidants, wetting agents, surfactants, suspending agents, propellants, absorption enhancers, absorption delaying agents and coating materials at least one.
- the pharmaceutical composition is a pharmaceutical preparation or an intermediate of a pharmaceutical preparation.
- the pharmaceutical composition is in solid form.
- solid form For example powder etc.
- the pharmaceutical composition can be formulated into various dosage forms, such as oral dosage forms, injection dosage forms, inhalation dosage forms, and transdermal dosage forms.
- dosage forms include solid, semisolid, liquid, and aerosol dosage forms; such as tablets, capsules, powders, injections, suspensions, suppositories, aerosols, granules, emulsions, syrups, elixirs, and the like.
- the pharmaceutical composition may be administered by any suitable method for delivering the composition or a component thereof or the active ingredient to the site of need.
- the method of administration can vary depending on a number of factors, for example, the nature of the components or active ingredients of the pharmaceutical composition, the site of possible or actual infection, the microorganisms (eg bacteria) involved, the severity of the infection, the age of the subject, and physical condition, etc.
- Some non-limiting examples of methods of administering the compositions to a subject in accordance with embodiments of the present invention include gastrointestinal, intravenous, subcutaneous, intramuscular, sublingual, dermal, otic Topical administration, ocular administration, oral inhalation administration, nasal inhalation administration.
- the embodiment of the second aspect of the present invention also provides the use of the pharmaceutical composition according to any embodiment of the first aspect of the present invention in preparing a medicament for preventing or treating bacterial infection.
- the bacteria are beta-lactamase-producing bacteria.
- some non-limiting examples of the bacteria include Streptococcus, Neisseria, Haemophilus influenzae, Salmonella, Moraxella catarrhalis, Acinetobacter, Escherichia coli), Pseudomonas aeruginosa, Staphylococcusaureus, Enterococcus, anaerobes, Enterobacter, Bacteroides, anaerobes, Proteus vulgaris, Proteus mirabilis Bacillus, Klebsiella (Klebsiella), Citrobacter (Citrobacter) and so on.
- the bacterial infection comprises a bacterial infectious disease.
- non-limiting examples of bacterial infections include: skin and soft tissue infection (SSTI), bone and/or joint infection, urogenital system infection, intraperitoneal infection Infection (intra-abdominal infection, IAI), respiratory system infection (respiratory system infection), bacteremia (bacteremia), meningitis and surgical site infection (surgical site infection, SSI) and so on.
- SSTI skin and soft tissue infection
- IAI intraperitoneal infection Infection
- respiratory system infection respiratory system infection
- bacteremia bacteremia
- meningitis surgical site infection
- a third aspect embodiment of the present invention provides a method of preventing or treating a bacterial infection comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition of any one of the first aspects of the present invention.
- the bacteria are beta-lactamase-producing bacteria.
- some non-limiting examples of the bacteria include Streptococcus, Neisseria, Haemophilus influenzae, Salmonella, Moraxella catarrhalis, Acinetobacter, Escherichia coli), Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus, anaerobic cocci, Enterobacter, Bacteroides, anaerobic cocci, Proteus vulgaris, mirabilis Proteus, Klebsiella, Citrobacter, etc.
- non-limiting examples of bacterial infections include: skin and soft tissue infections, bone and/or joint infections, genitourinary infections, intra-abdominal infections, respiratory infections, bacteremia, meningitis or surgery site infection, etc.
- the pharmaceutical composition may be administered by any suitable method for delivering the composition or its components or the active ingredient to the site of need.
- the method of administration can vary depending on a number of factors, for example, the nature of the components or active ingredients of the pharmaceutical composition, the site of possible or actual infection, the microorganisms (eg bacteria) involved, the severity of the infection, the age of the subject, and physical condition, etc.
- Some non-limiting examples of methods of administering the pharmaceutical composition to a subject according to embodiments of the present invention include gastrointestinal, intravenous, subcutaneous, intramuscular, sublingual, dermal, Auricular, ocular, oral inhalation, nasal inhalation.
- the specific dosage of the pharmaceutical composition described in the embodiment of the present invention may need to be adjusted accordingly due to various factors, these factors include but are not limited to: the severity of the subject's condition, the subject's age, gender, weight, Routes of administration and dosage forms, etc.
- ceftazime includes not only the compound molecule itself, but also its free acid, pharmaceutically acceptable salts, polymorphs, solvates, hydrates of any chemical purity, but not esters of the compound .
- ceftazidime in embodiments of the invention may be ceftazidime ((6R,7R)-7-[[[(2Z)-2-(2-amino-1,3-thiazole- 4-yl)-2-methoxyiminoacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2 -Carboxylic acid, CAS number: 65052-63-3), ceftazidime sodium ((6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(methoxy) Sodium imino)acetamido)-3-methyl-8-oxo-5
- sulbactam includes not only the compound molecule itself, but also its free acid, pharmaceutically acceptable salts, polymorphs, solvates, hydrates of any chemical purity.
- sulbactam in embodiments of the invention can be sulbactam ((2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-aza Bicyclo[3.2.0]heptane-2-carboxylic acid-4,4-dioxide), sulbactam sodium ((2S,5R)-3,3-dimethyl-7-oxo-4-thio Hetero-1-azabicyclo[3.2.0]heptane-2-carboxylate-4,4-dioxide) and the like.
- tazobactam includes not only the compound molecule itself, but also its free acid, pharmaceutically acceptable salts, polymorphs, solvates, hydrates of any chemical purity.
- tazobactam in embodiments of the invention can be tazobactam acid ((2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2 ,3-Triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide), tazobactam sodium ((2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-aza Bicyclo[3.2.0]heptane-2-carboxylate sodium 4,4-dioxide).
- ceftazidime includes not only the compound molecule itself, but also its free acid, pharmaceutically acceptable salts, polymorphs, solvates, hydrates, active metabolites, prodrugs of any chemical purity.
- the ceftazidime in embodiments of the present invention may be ceftazidime pentahydrate ((6R,7R)-7-[[(2-amino-4-thiazolyl)-[(1-carboxy-1-methyl ethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-methylpyridinium inner salt pentahydrate).
- cefoperazone includes not only the compound molecule itself, but also its free acid, pharmaceutically acceptable salts of any chemical purity, polymorphs, solvates, hydrates, active metabolites, prodrugs.
- the cefoperazone may be cefoperazone ((6R,7R)-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl in embodiments of the present invention ]-7-[(R)-2-(4-Ethyl-2,3-dioxo-1-piperazinecarbonylamino)-2-p-hydroxyphenyl-acetamido]-8-oxo- 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid), cefoperazone sodium ((6R,7R)-3-[[(1-methyl-1H-tetrazole-5 -yl)thio]methyl]-7-[(R)-2-(4-ethy
- cefotaxime includes not only the compound molecule itself, but also its free acid, pharmaceutically acceptable salts of any chemical purity, polymorphs, solvates, hydrates, active metabolites, prodrugs.
- the cefotaxime in embodiments of the present invention may be cefotaxime sodium ((6R,7R)-3-[(acetoxy)methyl]-7-[2-(2-aminothiazole) -4-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, sodium salt).
- ceftriaxone includes not only the compound molecule itself, but also its free acid, pharmaceutically acceptable salts of any chemical purity, polymorphs, solvates, hydrates, active metabolites, prodrugs.
- ceftriaxone in embodiments of the present invention may be ceftriaxone sodium ((6R,7R)-7-[[(2Z)-(2-aminothiazol-4-yl)(methoxy Imino)acetyl]amino]-3-[[(2-methyl-6-hydroxy-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)thio ]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-hydroxy acid disodium salt threesesquihydrate).
- free acid refers to the compound itself, which is the relative concept of a salt of a compound.
- “Pharmaceutically acceptable salt” refers to a pharmaceutically acceptable and relatively non-toxic inorganic/organic acid or base addition salt of a compound.
- “Polymorph” refers to a substance formed by microscopically different ordered arrangements of multiple compound molecules without changing the molecular structure of a single compound.
- “Solvate” refers to a substance formed by non-covalent bonding of compound molecules with a solvent. When the solvent is water, it can also be called “hydrate”.
- preventing refers to preventing or reducing the development of a given disease after use in the presence of factors that may trigger the given disease.
- treating includes delaying or reducing symptoms caused by a given disease.
- treatment specifically includes controlling the progression of the disease and associated symptoms.
- terapéuticaally effective amount refers to an amount sufficient to cure, alleviate or partially inhibit the clinical manifestations of a given disease.
- An amount suitable for accomplishing this purpose is defined as a “therapeutically effective amount”.
- the effective amount for each purpose depends on the severity of the disease or injury as well as factors such as the subject's weight and general state of health.
- composition refers to a mixture of one or more components or an association between more than one component.
- the components can be physically mixed together or physically separated from each other.
- the active ingredients may be present in the same pharmaceutical agent at the same time, or separately in multiple different pharmaceutical agents.
- the term “pharmaceutically acceptable” generally refers to use in the pharmaceutical arts and is not harmful to the product or to the subject.
- excipient may be any conventional excipient in the pharmaceutical field.
- the choice of specific excipients depends on the form of the pharmaceutical formulation or/and the mode of administration.
- infection includes the presence of bacteria in or on a subject that would benefit the subject if their growth was inhibited.
- the term “infection” refers to the undesired normal flora in addition to the presence of bacteria.
- infection includes infections caused by bacteria.
- skin and soft tissue infection also known as skin and skin structure infection, is an inflammatory disease caused by the invasion of the epidermis, dermis and subcutaneous tissue by pyogenic pathogens.
- urogenital infection is an infectious disease caused by the invasion of the urogenital system by pathogenic bacteria for various reasons.
- intra-abdominal infection refers to a series of intra-abdominal infectious diseases, mainly including infection of a single organ in the abdominal cavity (such as acute cholecystitis, acute appendicitis, etc.), peritonitis, and intra-abdominal abscess, and can also be involved according to the scope of infection And the severity is divided into simple intra-abdominal infection and complex intra-abdominal infection.
- respiratory infection is a disease in which pathogenic microorganisms invade and multiply in the respiratory system.
- bacteria is the entry of bacteria from an inflammatory lesion into the bloodstream through blood vessels or lymphatics, where the bacteria can be found in the blood, but the patient has no symptoms of systemic toxicity.
- meningitis is a serious infectious disease of the central nervous system, which can be caused by many bacteria, among which meningococcus causes the most, followed by influenza bacillus, pneumococcus, Escherichia coli and other gram Positive bacilli, staphylococcus, listeria, anaerobic bacteria, etc.
- surgical site infection includes both surgical incision infections and infections of surgical organs and surrounding tissues.
- antibiotic refers to any substance, compound or combination of substances or combination of compounds capable of: (i) inhibiting, reducing or preventing the growth of bacteria; (ii) inhibiting or reducing the ability of bacteria to produce an infection in a subject or (iii) inhibiting or reducing the ability of bacteria to multiply or remain infectious in the environment.
- antibiotic also refers to compounds capable of reducing bacterial infectivity or virulence.
- beta-lactam antibiotic refers to a compound that has antibiotic properties and contains a beta-lactam core in its molecular structure.
- beta lactamase refers to any enzyme or protein or any other that breaks down a beta lactam ring.
- beta-lactamase includes enzymes produced by bacteria and having the ability to partially or fully hydrolyze the beta-lactam rings in beta-lactam antibiotics.
- beta-lactamase inhibitor refers to a compound capable of partially or completely inhibiting the activity of one or more beta-lactamases.
- the term “subject” refers to vertebrates or invertebrates, including mammals.
- the term “subject” includes humans, animals, birds, fish or amphibians. Typical, non-limiting examples of “subjects” include humans, cats, dogs, horses, sheep, cows, pigs, lambs, rats, mice and guinea pigs.
- the combination or combination of ⁇ -lactamase inhibitors and ⁇ -lactam antibiotics is more common, and most of them discuss the changes in the bacteriostatic effect after the combination of the two, usually using a larger proportion of antibiotics
- a small proportion of ⁇ -lactamase inhibitor is assisted to provide anti-enzyme activity, so as to play a synergistic role; and the improvement of drug stability is mainly based on the crystal form of the raw drug, the type of excipients, the Start with the pH value of the composition, packaging container, etc.
- the use of this stable ⁇ -lactamase inhibitor in combination with ⁇ -lactam antibiotics can better restore sensitivity to bacteria and better improve the bacteriostatic effect of ⁇ -lactam antibiotics .
- the ratios in the compositions of the present invention are calculated based on the free acid of the components.
- the drugs used in the embodiments of the present invention are all APIs.
- Example 2 The effect of different contents of ceftazidime on hygroscopicity of ⁇ -lactamase inhibitor
- ceftazidime dosage was further studied.
- compositions containing sulbactam and ceftazidime in different proportions, and compositions containing tazobactam and ceftamid in different proportions were prepared respectively.
- Moisture test was carried out in the same way. The results are shown in Table 2. It can be seen from Table 2 that not all ratios of ceftazidime can reduce the hygroscopicity of ⁇ -lactamase inhibitors. , Cefetamet has a better effect of reducing hygroscopicity.
- Table 2 The weight gain rate of the composition of ⁇ -lactamase inhibitor and different dosage of ceftazidime under the same humidity
- the preparation of antibiotic preparations often requires multiple mixing, and operations such as mixing and sub-packaging may deteriorate the stability of materials (especially hygroscopic materials). Therefore, by increasing the mixing time and times to simulate industrial antibiotic preparations preparation.
- Each sample to be tested was placed for 6 months in an environment with a temperature of 40 °C ⁇ 2 °C and a humidity of 75% ⁇ 5%, and high performance liquid chromatography (HPLC) was used to detect ⁇ -lactamase in each sample in October and June respectively.
- HPLC high performance liquid chromatography
- the content of inhibitors and the content of main impurities were used to investigate the changes in the quality of the samples to be tested.
- HPLC detection conditions are as follows (refer to the US Pharmacopoeia):
- Sulbactam chromatographic column 4mm ⁇ 15cm; 3 ⁇ m packing L1; mobile phase as shown in Table 3; detection wavelength 215nm.
- Tazobactam Column: 4.6mm ⁇ 25cm; 5 ⁇ m packing L1, mobile phase: dissolve 1.32g of diammonium hydrogen phosphate in 750mL of water, adjust the pH to 2.5 with 5% v/v phosphoric acid, and then dilute to 1000mL with water , 30 mL of acetonitrile was added, and mixed; the detection wavelength was 210 nm.
- Mobile phase A in Table 3 is 5.4g/L potassium dihydrogen phosphate adjusted to pH 4.0 with dilute phosphoric acid.
- the ring-opening impurity of sulbactam in Table 4 is (2S)-2-amino-3-methyl-3-sulfinylbutyric acid.
- the content of tazobactam and the content of main impurities in each sample in 0 months and 6 months are shown in Table 5.
- the results show that after 6 months, the active ingredient content of the combination of ceftazidime and tazobactam is more than 99.1% , the content of ring-opening impurities was 0.13-0.22%, and the change was not significant compared with 0 months; while the active ingredient content of tazobactam alone dropped to 98.1% after 6 months, and the content of ring-opening impurities was 0.82 %, compared with 0 months, the content of active ingredients decreased significantly, and the content of ring-opening impurities increased significantly; it can be seen that the addition of ceftazidime significantly inhibited the degradation of active ingredients, reduced the content of ring-opening impurities, and improved the composition. stability of the material.
- the ring-opening impurity of tazobactam in Table 5 is (2S,3S)-2-amino-3-sulfinyl-4-(1H-1,2,3-triazol-1-yl)butanoic acid .
- the stability test results show that the combination of ⁇ -lactamase inhibitor and ceftazidime has higher active ingredient content and lower impurity content, and has better stability than ⁇ -lactamase inhibitor alone. sex.
- the ring-opening impurities increased significantly, indicating that the quality of the drug is still unstable.
- the ⁇ -lactamase inhibitor mainly relies on the lactam ring to exert its inhibitory effect, its ring-opening impurities will not have the ability to inhibit the enzyme at all, and may reverse the binding between the ⁇ -lactamase inhibitor and the enzyme. An increase in impurities may adversely affect drug efficacy.
- Example 4 ⁇ -lactamase inhibitor composition is used to prepare compound antibiotics
- the ⁇ -lactamase inhibitor composition with stable quality in Example 3 is particularly suitable for preparing compound antibiotics.
- it is combined with the third-generation cephalosporins ceftazidime, cefoperazone, cefotaxime, ceftriaxone, etc. to form various compound preparations.
- cephalosporins ceftazidime, cefoperazone, cefotaxime, ceftriaxone, etc. to form various compound preparations.
- One of the compositions in Example 3 is exemplified below, and other compositions can be compared.
- ceftriaxone Take commercially available ceftriaxone, pass through a 200-mesh sieve after pulverizing, take 2000 g and put it into a single-cone spiral-ribbon mixer, and take another sulbactam+ceftazidime (100:1) composition prepared according to the method in Example 2 1010g, put into the same single-cone spiral-ribbon mixer, fully mixed, and packaged under aseptic conditions to obtain compound antibiotic injection—ceftriaxone-sulbactam (2:1).
- ceftriaxone-tazobactam (3:1), ceftriaxone-tazobactam (6:1), cefotaxime-tazobactam (6:1), cefotaxime (6:1) were prepared Bactam (2:1), ceftazidime tazobactam (3:1), ceftazidime tazobactam (5:1), cefoperazone tazobactam (8:1), cefoperazone tazobactam (4:1), cefoperazone-tazobactam (6:1), cefoperazone-sulbactam (3:1), cefoperazone-sulbactam (2:1), cefoperazone-sulbactam ( 1:1) and other compound preparations.
- ceftriaxone sulbactam contrast agent (2:1) ceftriaxone Tazobactam Contrast Media (3:1), Cefotaxime Tazobactam Contrast Media (6:1), Cefotaxime Sulbactam Contrast Media (2:1), Cefotaxime Tazobactam Contrast Media (3:1) :1), cefoperazone-tazobactam contrast agent (8:1), cefoperazone-sulbactam contrast agent (1:1), etc.
- cefotaxime sulbactam (2:1), cefotaxime tazobactam (6:1), cefotaxime sulbactam contrast agent (2:1) and cefotaxime tazobactam were selected for comparison (6:1), as well as commercially available cefotaxime injection, to test the bacteriostatic activity of these antibiotics.
- Test method 37 strains of clinically isolated ⁇ -lactamase-producing Escherichia coli were tested for drug sensitivity according to the CLSI micro-broth dilution method, and the MIC value of each drug was determined. The drug dilution concentration range was 0.03-256 ⁇ g/mL, and the MIC was the lowest drug concentration that inhibited the visible growth of bacteria after 24 hours of incubation at 37°C. The results are shown in Table 6.
- the test results showed that the ⁇ -lactamase-producing bacteria were resistant to individual antibiotics.
- Combination of ⁇ -lactamase inhibitors and antibiotics can make bacteria resensitized to antibiotics.
- the compound antibiotic prepared from the ⁇ -lactamase inhibitor composition (including ceftazidime) according to the embodiment of the present invention has stronger antibacterial activity compared with ordinary compound antibiotics, and shows that the MIC 50 and the MIC range are both smaller than those of ordinary compound antibiotics. .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Les modes de réalisation de la présente invention concernent le domaine technique de la médecine, en particulier une composition inhibitrice de bêta-lactamases présentant une qualité stable, une utilisation et une méthode associées. La composition pharmaceutique des modes de réalisation de la présente invention présente une hygroscopicité améliorée et une meilleure stabilité, de façon que la stabilité des substances dans une méthode de préparation puisse être assurée et la composition pharmaceutique est particulièrement appropriée pour la préparation ultérieure d'antibiotiques composés. De plus, des expériences montrent que la composition inhibitrice de bêta-lactamases des modes de réalisation de la présente invention peut davantage améliorer la sensibilité des antibiotiques à des bactéries résistantes aux médicaments, et les antibiotiques composés préparés présentent une activité antimicrobienne plus forte vis-à-vis des bactéries résistantes aux médicaments.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180001071.1A CN113194943B (zh) | 2021-03-22 | 2021-03-22 | 一种具有稳定性和抑菌活性的含有头孢噻肟舒巴坦或头孢噻肟他唑巴坦的药物组合物 |
PCT/CN2021/082063 WO2022198378A1 (fr) | 2021-03-22 | 2021-03-22 | Composition inhibitrice de bêta-lactamases présentant une qualité stable, utilisation et méthode associées |
CN202211296199.8A CN115581700A (zh) | 2021-03-22 | 2021-03-22 | 质量稳定抑菌活性高的含头孢噻肟舒巴坦或头孢噻肟他唑巴坦的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2021/082063 WO2022198378A1 (fr) | 2021-03-22 | 2021-03-22 | Composition inhibitrice de bêta-lactamases présentant une qualité stable, utilisation et méthode associées |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022198378A1 true WO2022198378A1 (fr) | 2022-09-29 |
Family
ID=76976943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/082063 WO2022198378A1 (fr) | 2021-03-22 | 2021-03-22 | Composition inhibitrice de bêta-lactamases présentant une qualité stable, utilisation et méthode associées |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN113194943B (fr) |
WO (1) | WO2022198378A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022198378A1 (fr) * | 2021-03-22 | 2022-09-29 | 广州新创忆药物临床研究有限公司 | Composition inhibitrice de bêta-lactamases présentant une qualité stable, utilisation et méthode associées |
CN114025767A (zh) * | 2021-09-18 | 2022-02-08 | 湘北威尔曼制药股份有限公司 | 一种含有头孢哌酮钠和他唑巴坦钠的药物组合物及其应用 |
CN116808047A (zh) * | 2022-03-22 | 2023-09-29 | 南京优科生物医药股份有限公司 | 一种头孢噻肟或其盐和他唑巴坦或其盐的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1616100A (zh) * | 2004-10-14 | 2005-05-18 | 崔晓廷 | β-内酰胺类抗生素复方口服制剂及其制备方法 |
CN1637002A (zh) * | 2003-11-28 | 2005-07-13 | 浙江永宁制药厂 | 耐β—内酰胺酶的头孢菌素酯化合物及其盐 |
CN1850047A (zh) * | 2006-06-01 | 2006-10-25 | 济南帅华医药科技有限公司 | 一种含β-内酰胺酶抑制剂和头孢菌素的缓释制剂及其应用 |
CN101837126A (zh) * | 2010-04-27 | 2010-09-22 | 四川方向药业有限责任公司 | 头孢类抗菌药物组合物及其药物制剂 |
CN113194943A (zh) * | 2021-03-22 | 2021-07-30 | 广州新创忆药物临床研究有限公司 | 一种质量稳定的β内酰胺酶抑制剂组合物及其用途和方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2568959A2 (fr) * | 2010-05-14 | 2013-03-20 | Mahmut Bilgic | Formulations comprenant une céphalosporine et un acide clavulanique de troisième génération |
US20110288063A1 (en) * | 2010-05-19 | 2011-11-24 | Naeja Pharmaceutical Inc. | Novel fused bridged bicyclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors |
WO2013014497A1 (fr) * | 2011-07-26 | 2013-01-31 | Wockhardt Limited | Compositions pharmaceutiques comprenant un antibiotique bêta-lactame, du sulbactam et un inhibiteur de bêta-lactamase |
NZ706734A (en) * | 2012-09-03 | 2016-05-27 | Wockhardt Ltd | Pharmaceutical compositions useful for the treatment or control of bacterial infections |
TR201511982A2 (tr) * | 2015-09-29 | 2017-04-21 | Serra Karaagac | Anti̇bakteri̇yel formülasyonlar |
-
2021
- 2021-03-22 WO PCT/CN2021/082063 patent/WO2022198378A1/fr active Application Filing
- 2021-03-22 CN CN202180001071.1A patent/CN113194943B/zh active Active
- 2021-03-22 CN CN202211296199.8A patent/CN115581700A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1637002A (zh) * | 2003-11-28 | 2005-07-13 | 浙江永宁制药厂 | 耐β—内酰胺酶的头孢菌素酯化合物及其盐 |
CN1616100A (zh) * | 2004-10-14 | 2005-05-18 | 崔晓廷 | β-内酰胺类抗生素复方口服制剂及其制备方法 |
CN1850047A (zh) * | 2006-06-01 | 2006-10-25 | 济南帅华医药科技有限公司 | 一种含β-内酰胺酶抑制剂和头孢菌素的缓释制剂及其应用 |
CN101837126A (zh) * | 2010-04-27 | 2010-09-22 | 四川方向药业有限责任公司 | 头孢类抗菌药物组合物及其药物制剂 |
CN113194943A (zh) * | 2021-03-22 | 2021-07-30 | 广州新创忆药物临床研究有限公司 | 一种质量稳定的β内酰胺酶抑制剂组合物及其用途和方法 |
Also Published As
Publication number | Publication date |
---|---|
CN115581700A (zh) | 2023-01-10 |
CN113194943A (zh) | 2021-07-30 |
CN113194943B (zh) | 2022-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5809750B2 (ja) | β−ラクタム抗生物質、スルバクタム及びβ−ラクタマーゼ阻害薬を含む医薬組成物 | |
JP7245289B2 (ja) | 細菌感染症の処置方法 | |
JP6870029B2 (ja) | セフトロザン抗生物質組成物 | |
CN113194943B (zh) | 一种具有稳定性和抑菌活性的含有头孢噻肟舒巴坦或头孢噻肟他唑巴坦的药物组合物 | |
EP1841432B1 (fr) | Compositions destinees a lutter contre la resistance aux antibiotiques induite par la beta-lactamase au moyen des inhibiteurs de la beta-lactamase utiles pour injection | |
US20090275552A1 (en) | Therapy for Treating Resistant Bacterial Infections | |
US11278622B2 (en) | Ceftolozane antibiotic compositions | |
US20200093814A1 (en) | Combination therapy with amidine substituted beta-lactam compounds and beta-lactamase inhibitors for infections with antibiotic resistant bacterial strains | |
RU2524665C2 (ru) | Композиции и способы лечения, включающие цефтаролин | |
EP2066302A2 (fr) | Compositions stabilisatrices pour antibiotiques et leurs méthodes d'utilisation | |
AU2015200599B2 (en) | Ceftolozane Antibiotic Compositions | |
WO2024128238A1 (fr) | Agent thérapeutique pour infection bactérienne | |
Vilvanathan | Penicillins, Cephalosporins, and Other b-Lactam Antibiotics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21932013 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21932013 Country of ref document: EP Kind code of ref document: A1 |